Remove Compounding Remove Magazine Remove Packaging
article thumbnail

Hims & Hers shares plummet 35% as Novo Nordisk pulls partnership plug

Pharmaceutical Technology

Robert Barrie June 24, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Compounded GLP-1RA medication has become a key revenue driver for Hims & Hers’ telehealth platform. Hims & Hers’ revenue has been soaring on the back of its compounded glucagon-like peptide-1 receptor agonist (GLP-1RA) sales.

article thumbnail

How AI and machine learning are transforming drug discovery

Pharmaceutical Technology

AI models can predict molecular interactions and assist in designing novel compounds tailored to specific therapeutic goals. AI-driven screening methods, such as High-Throughput Screening (HTS), allow researchers to rapidly evaluate large libraries of compounds. Can pharma tariffs “Make America Manufacture Again”?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novo Nordisk signs $812m research deal with Deep Apple for non-GLP-1 drugs

Pharmaceutical Technology

Novo Nordisk is eyeing a cardiometabolic drug market future that is not purely dominated by incretins, after signing a $812m partnership with Deep Apple Therapeutics to access novel compounds for obesity and other diseases. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights.

article thumbnail

Juvenescence enhances AI drug discovery with Ro5 acquisition

Pharmaceutical Technology

Ro5’s AI Chemistry Platform also uses advanced machine learning models and cheminformatics tools for quick compound discovery and design from hit identification to lead optimisation. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights.

article thumbnail

Draig secures $140m for neuropsychiatric disorder therapies

Pharmaceutical Technology

These compounds have the potential for addressing a spectrum of neuropsychiatric disorders that currently lack adequate treatment options. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights.

article thumbnail

Novo Nordisk seeks digital health partners to boost GLP-1RA weight loss outcomes

Pharmaceutical Technology

It recently initiated two more Phase III trials of its candidate CagriSema, as well as inking an $812m partnership with Deep Apple Therapeutics to access novel compounds, not GLP-1RAs, for obesity and other diseases. Can pharma tariffs “Make America Manufacture Again”? Give your business an edge with our leading industry insights.

article thumbnail

Customs simplified: the need to streamline pharma shipments

Pharmaceutical Technology

Tariffs and trade disputes are further compounding this challenge, affecting the cost structure of pharma businesses. Can pharma tariffs “Make America Manufacture Again”? The complexity of customs regulations also means lead times for shipping protract, which can have a negative impact on clinical trials and product availability.